271 related articles for article (PubMed ID: 31680584)
1. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Derman BA; Streck M; Wynne J; Christ TN; Curran E; Stock W; Knoebel RW
Leuk Lymphoma; 2020 Mar; 61(3):614-622. PubMed ID: 31680584
[TBL] [Abstract][Full Text] [Related]
2. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM; Morgades M; Montesinos P; Martino R; Barba P; Soria B; Bermúdez A; Moreno MJ; González-Campos J; Vives S; Gil C; Abella E; Guàrdia R; Martínez-Carballeira D; Martínez-Sánchez P; Amigo ML; Mercadal S; Serrano A; López-Martínez A; Vall-Llovera F; Sánchez-Sánchez MJ; Peñarrubia MJ; Calbacho M; Méndez JA; Bergua J; Cladera A; Tormo M; García-Belmonte D; Feliu E; Ciudad J; Orfao A;
Leuk Lymphoma; 2018 Jul; 59(7):1634-1643. PubMed ID: 29165013
[TBL] [Abstract][Full Text] [Related]
4. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.
Patel B; Kirkwood AA; Dey A; Marks DI; McMillan AK; Menne TF; Micklewright L; Patrick P; Purnell S; Rowntree CJ; Smith P; Fielding AK
Leukemia; 2017 Jan; 31(1):58-64. PubMed ID: 27480385
[TBL] [Abstract][Full Text] [Related]
5. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
6. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
7. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
8. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
9. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
10. Activity and toxicity of intramuscular 1000 iu/m
Sidhu J; Masurekar AN; Gogoi MP; Fong C; Ioannou T; Lodhi T; Parker C; Liu J; Kirkwood AA; Moorman AV; Das K; Goulden NJ; Vora A; Saha V; Krishnan S
Br J Haematol; 2022 Jul; 198(1):142-150. PubMed ID: 35348200
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase activities during intensified treatment with pegylated
Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
[TBL] [Abstract][Full Text] [Related]
12. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
13. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
15. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
16. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
[TBL] [Abstract][Full Text] [Related]
18. Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.
Hanbali A; Kotb A; El Fakih R; Alfraih F; Ahmed SO; Shaheen M; Hashmi S; Alhayli S; Alahmari A; Riash MA; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):670-677. PubMed ID: 31377206
[TBL] [Abstract][Full Text] [Related]
19. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
20. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]